While ResMed recorded US$4.69 billion in sales for FY24, up from US$4.22 billion in FY23, the company is forecast to achieve US$5.25 billion in FY25. Led by growth in the U.S., ResMed’s first half ...

ResMed Inc. (NYSE:RMD – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the firm, Marketbeat.com reports.

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

ResMed Inc. (NYSE:RMD – Get Free Report) shares gapped up prior to trading on Monday after UBS Group upgraded the stock from a hold rating to a strong-buy rating. The stock had previously closed ...

BACKGROUND Many patients with sleep apnoea/hypopnoea syndrome (SAHS) find nasal continuous positive airway pressure (CPAP) treatment unsatisfactory due to side effects related to mouth air leakage. A ...